Craig T. Jordan Ph.D. is the Nancy Carroll Allen Professor and Chief of Hematology at the University of Colorado. He has been studying human leukemia stem cells for the past 25 years, with a focus on the development of novel therapies. Research from his team led to the first direct demonstration of leukemia stem cell targeting in AML patients using venetoclax-based therapy, as well as multiple discoveries related to the molecular mechanisms driving resistance to venetoclax. Dr. Jordan completed his doctoral studies in 1991 at Princeton University with a focus on the molecular biology of hematopoietic stem cells. He then went on to perform post-doctoral studies at the Whitehead Institute. In 2013 he took his present position at the University of Colorado. Dr. Jordan has published nearly 200 original research articles, reviews, and chapters. He has had continuous NIH funding for over 20 years and has received multiple honors including the NCI Outstanding Investigator award.